Dupilumab's Long-Term Lab Safety in Young Patients With AD: 3-Year Phase 3 Data

Amy S. Paller, Northwestern University The Feinberg School of Medicine, Wilmette, IL, United States; John C.. Su, Monash University, Eastern Health and MCRI, Royal Children’s Hospital, Melbourne, Victoria, Australia; Elaine Siegfried, Saint Louis University and Cardinal Glennon Children's Hospital, St Louis, MO, United States; Michael J.. Cork, University of Sheffield + Sheffield Children's NHS FT, Sheffield, England, United Kingdom; Lawrence F.. Eichenfield, University of California, San Diego and Rady Children’s Hospital, San Diego, San Diego, CA, United States; Hideaki Morita, National Research Institute for Child Health and Development, Tokyo, Tokyo, Japan; Michael P. Van Spall, Sanofi, Montreal, PQ, Canada; Faisal A. Khokhar, Regeneron Pharmaceuticals Inc., New York, NY, United States; Yonghao Ma, Regeneron Pharmaceuticals Inc., Dripping Springs, TX, United States; Thu Tong, Regeneron Pharmaceuticals Inc., NY, NY, United States; Randy Prescilla, Sanofi, Cambridge, MA, United States